GSTM1 and kidney disorder: At the KDIGO (Kidney Disease: Improving Global Outcomes) conference, some credence was given to the results of the PIVOTAL trial, but concerns over the lack of comparison versus oral supplementation and placebo were expressed and the need for further study was mentioned for the management of iron and anemia based on individual CKD patient characteristics and not only on population Hb and TSAT values [23].